{{Rsnum
|rsid=2498804
|Chromosome=14
|position=104766758
|Orientation=minus
|GMAF=0.41
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene=LOC102723342
|Gene_s=LOC102723342
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 42.6 | 46.3 | 11.1
| HCB | 13.3 | 50.4 | 36.3
| JPT | 16.1 | 57.1 | 26.8
| YRI | 59.3 | 34.3 | 6.4
| ASW | 42.1 | 40.4 | 17.5
| CHB | 13.3 | 50.4 | 36.3
| CHD | 12.0 | 49.1 | 38.9
| GIH | 22.2 | 50.5 | 27.3
| LWK | 54.6 | 35.2 | 10.2
| MEX | 19.6 | 53.6 | 26.8
| MKK | 54.9 | 39.2 | 5.9
| TSI | 48.0 | 49.0 | 2.9
| HapMapRevision=28
}}{{PMID Auto
|PMID=20447721
|Title=PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy
|OA=1
}}

{{PMID Auto
|PMID=22277669
|Title=Genetic overlap between schizophrenia and bipolar disorder: A study with AKT1 gene variants and clinical phenotypes
}}

{{PMID Auto
|PMID=18497887
|Title=Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans.
|OA=1
}}

{{PMID Auto
|PMID=19164214
|Title=Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
|OA=1
}}

{{PMID Auto
|PMID=19931325
|Title=No association between AKT1 polymorphism and schizophrenia: a case-control study in a Korean population and a meta-analysis.
}}

{{PMID Auto
|PMID=20046382
|Title=AKT1 Gene Polymorphisms and Obstetric Complications in the Patients with Schizophrenia.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}